{"filing":{"accession_number":"0001104659-26-080432","cik":"0001751912","ticker":"NGEN","company_name":"NERVGEN PHARMA CORP.","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"tm2619503d3_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1751912/000110465926080432/tm2619503d3_6k.htm"},"events":[{"id":16011,"run_id":14282,"accession_number":"0001104659-26-080432","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is an at-the-market (ATM) sales agreement dated July 2, 2026, under which NervGen Pharma Corp. authorizes Leerink Partners LLC to sell up to US$50,000,000 of common shares on an ongoing basis. The agreement explicitly permits sales \"at market prices\" through Nasdaq and other U.S. trading venues (Section 3), with the Company retaining discretion to issue Placement Notices controlling timing and volume. This is a classic dilutive equity issuance arrangement that would materially affect shareholder interests through potential share dilution.","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13958,"accession_number":"0001104659-26-080432","item_number":"EX-99.1","item_title":"tm2619503d3_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is an at-the-market (ATM) sales agreement dated July 2, 2026, under which NervGen Pharma Corp. authorizes Leerink Partners LLC to sell up to US$50,000,000 of common shares on an ongoing basis. The agreement explicitly permits sales \"at market prices\" through Nasdaq and other U.S. trading venues (Section 3), with the Company retaining discretion to issue Placement Notices controlling timing and volume. This is a classic dilutive equity issuance arrangement that would materially affect shareholder interests through potential share dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:24:38.481614+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13958,"accession_number":"0001104659-26-080432","item_number":"EX-99.1","item_title":"tm2619503d3_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is an at-the-market (ATM) sales agreement dated July 2, 2026, under which NervGen Pharma Corp. authorizes Leerink Partners LLC to sell up to US$50,000,000 of common shares on an ongoing basis. The agreement explicitly permits sales \"at market prices\" through Nasdaq and other U.S. trading venues (Section 3), with the Company retaining discretion to issue Placement Notices controlling timing and volume. This is a classic dilutive equity issuance arrangement that would materially affect shareholder interests through potential share dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:24:38.481614+00:00","company_name":"NERVGEN PHARMA CORP.","ticker":"NGEN","filing_date":"2026-07-02"}]}